La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Poseida Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Poseida Therapeutics..

Poseida Therapeutics (NASDAQ:PSTX) Azioni, Catena delle Opzioni

Poseida Therapeutics

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

Poseida Therapeutics, Inc. - Common Stock

Poseida Therapeutics Inc

HC Wainwright &amp; Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) with a Buy and maintains $20 price target.

News

Price Target

Reiteration

Analyst Ratings

PSTX

HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target

WIIM

Poseida Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.

Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $(0.41) by 151.22 percent. This is a 160 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $71.75 million which beat the analyst consensus estimate of $16.27 million by 340.98 percent. This is a 667.19 percent increase over sales of $9.35 million the same period last year.

Earnings

Earnings Beats

Poseida Therapeutics Q3 EPS $0.21 Beats $(0.41) Estimate, Sales $71.75M Beat $16.27M Estimate

New preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM) and enhanced potency to better target solid tumors will be presented at SITC
Additional profiling of patient responses in P-BCMA-ALLO1 Phase 1 Arm C and preclinical P-CD19CD20-ALLO1 to be presented at ASH
SAN DIEGO, Nov. 5, 2024 /PRNewswire/ --&nbsp;Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced new preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM), along with platform enhancements aimed at enhancing potency and improving targeting of solid tumors, will be presented at the Society for Immunotherapy of Cancer (SITC) 39th&nbsp;Annual Meeting in Houston, November 6-10.

Biotech

General

Poseida Therapeutics To Present Clinical And Preclinical Data On Investigational Allogeneic CAR-T Cell Therapies At SITC 2024 And ASH 2024

Data to be highlighted in a Distinguished Industry Oral Abstract presentation at the American College of Allergy, Asthma &amp; Immunology (ACAAI) 2024 Scientific Meeting
SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune, and rare diseases, today announced the upcoming presentation of new preclinical data supporting the potential of P-KLKB1-101, a liver-directed genetic medicine that uses the Company's Cas-CLOVER&#x2122;&nbsp;Site-Specific Gene Editing System, for the treatment of patients with hereditary angioedema (HAE). The data showed high-fidelity KLKB1 gene editing for the targeted correction of HAE, the ability for controlled dose response, favorable tolerability and liver editing within the predicted therapeutic range.

Poseida Therapeutics To Present New Preclinical Data Supporting Non-Viral Gene Editing With P-KLKB1-101 For The Treatment Of Hereditary Angioedema

Poseida Therapeutics Announces Nomination Of New CAR-T Development Candidate Under Collaboration with Roche, Triggering $15M Milestone Payment To Poseida

Poseida Therapeutics Reports Interim Phase 1 Results For Allogeneic CAR-T Therapy P-BCMA-ALLO1 Showing 91% ORR

Poseida Therapeutics shares are trading higher after the company received Regenerative Medicine Advanced Therapy designation from the FDA for P-BCMA-ALLO1 in relapsed/refractory multiple myeloma.

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy Designation From The FDA For P-BCMA-ALLO1 In Relapsed/Refractory Multiple Myeloma

Latest data from Poseida's lead investigational allogeneic CAR-T program, which is based on the Company's unique stem cell memory T cell (TSCM) platform
Company to host conference call on Saturday, September 28, 2024, at 1 PM ET / 10 AM PT to review the P-BCMA-ALLO1 Phase 1 IMS oral presentation data
Poseida initiates P-BCMA-ALLO1 Phase 1b clinical trial in patients with multiple myeloma, generating $20 million payment from Roche
SAN DIEGO, Sept. 5, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, announced today that new clinical data from an ongoing Phase 1 study of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma will be presented in an oral session at the 21st International Myeloma Society (IMS) Annual Meeting, which is being held in Rio de Janeiro from September 25-28, 2024. The Company is developing P-BCMA-ALLO1, an investigational off-the-shelf allogeneic CAR-T cell therapy enriched for stem cell memory T cells (TSCM), in partnership with Roche for the treatment of relapsed/refractory multiple myeloma.

Contracts

RHHBY

Poseida Therapeutics To Present New Clinical Data From Phase 1 Study Of Allogeneic CAR-T P-BCMA-ALLO1 In Patients With Relapsed/Refractory Multiple Myeloma At 21st International Myeloma Society Annual Meeting; Initiation Of P-BCMA-ALLO1 Phase 1b Clinical Trial In Patients With Multiple Myeloma, Generated $20M Payment From Roche

Reactivation of P-BCMA-101&nbsp;CAR-T cells and a repeat stringent complete response (sCR) more than 3 years after original CAR-T therapy
Demonstrates potential of stem cell memory T cells (TSCM), a key differentiator for Poseida's CAR-T programs&nbsp;
SAN DIEGO, Sept. 4, 2024 /PRNewswire/ --&nbsp;Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, highlighted new data from a case study of a patient with relapsed multiple myeloma treated in a clinical trial of P-BCMA-101, the Company's original investigational T stem cell memory (TSCM)-rich BCMA targeting autologous CAR-T cell therapy. The data were presented in an oral session at the Society of Hematologic Oncology (SOHO) Twelfth Annual Meeting in Houston.

Poseida Therapeutics Presented Case Study Demonstrating Reactivation Of CAR-T Therapy With A T-Cell Engager In A Patient With Relapsed Multiple Myeloma

Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.41) by 21.95 percent. This is unchanged from the same period last year. The company reported quarterly sales of $25.97 million which beat the analyst consensus estimate of $15.43 million by 68.33 percent. This is a 29.78 percent increase over sales of $20.01 million the same period last year.

Poseida Therapeutics Q2 EPS $(0.32) Beats $(0.41) Estimate, Sales $25.97M Beat $15.43M Estimate

<h3>Gainers</h3>
<ul>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares moved upwards by 11.1% to $1.3 during Tuesday's after-market session. The company's market cap stands at $24.4 million. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) stock increased by 6.09% to $0.69. The company's market cap stands at $26.1 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock increased by 5.71% to $1.11. The company's market cap stands at $7.0 million. </li>
<li>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) stock moved upwards by 4.99% to $0.54. The market value of their outstanding shares is at $121.2 million. </li>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock moved upwards by 4.86% to $5.82. The market value of their outstanding shares is at $185.1 million. </li>
<li>Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) stock moved upwards by 4.72% to $2.88. The market value of their outstanding shares is at $279.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares fell 15.3% to $0.23 during Tuesday's after-market session. The company's market cap stands at $14.6 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock decreased by 14.88% to $0.4. The company's market cap stands at $5.6 million. </li>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) shares decreased by 14.12% to $0.46. The market value of their outstanding shares is at $3.6 million. </li>
<li>Adlai Nortye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANL#NASDAQ">ANL</a>) stock decreased by 11.5% to $3.31. The company's market cap stands at $122.1 million. </li>
<li>Avid Bioservices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDMO#NASDAQ">CDMO</a>) stock declined by 8.89% to $7.28. The company's market cap stands at $462.1 million. </li>
<li>Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) shares decreased by 8.29% to $1.55. The company's market cap stands at $45.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AMIX

BSGM

CAPR

CDMO

CLDI

GOSS

IMRX

THMO

UNCY

VERO

12 Health Care Stocks Moving In Tuesday's After-Market Session

Poseida Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and improve treatment options. Given this favorable trend, it could be wise to watch strong pharma stocks such as Vertex Pharmaceuticals (VRTX), Wave Life Sciences (WVE), and Poseida Therapeutics (PSTX). Read more... In 2024, gene therapy is gaining traction, driven by breakthroughs like CRISPR technology and high-cost therapies. Growing regulatory approvals and innovative solutions for rare diseases position gene therapy as a promising investment opportunity in the pharmaceutical landscape.
Amid this favorable backdrop, investors could consider keeping an eye on strong pharma stocks: Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>), Wave Life Sciences Ltd. (<a href="https://stocknews.com/stock/WVE/">WVE</a>), and Poseida Therapeutics, Inc. (<a href="https://stocknews.com/stock/PSTX/">PSTX</a>).
Gene therapy is driving growth in the pharmaceutical industry by addressing complex conditions through innovations like recombinant AAV vectors and peptide-modified AAV capsids. These advancements improve treatment options and patient outcomes, opening market opportunities. Global pharmaceutical revenues are projected to reach $1.16 trillion this year, with a <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">6.2% CAGR</a>, reaching $1.47 trillion by 2028. Also, the global gene therapy market is projected to grow at <a href="https://www.grandviewresearch.com/industry-analysis/gene-therapy-market">a CAGR of 18.9%</a> until 2030.
In addition, gene therapy is revolutionizing biotech innovation by shortening drug development timelines. Enhanced delivery methods and technologies like CRISPR improve precision and efficacy, reigniting interest in the industry. As a result, the pharmaceutical sector is positioned for robust growth, with the global biotechnology market expected to reach $3.88 trillion by 2030, at a <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">CAGR of 14%</a>.
Considering these conducive trends, let's take a look at the fundamentals of the three pharma picks.
Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>)
VRTX is a biotechnology company that develops and commercializes therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO.
On August 7, 2024, VRTX announced a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access CASGEVY. This CRISPR/Cas9 gene-edited therapy is one of the first medicines funded by NHS England's Innovative Medicines Fund.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebit.asp">EBIT</a> margin, VRTX's 40.61% is considerably higher than the 2.64% industry average. Likewise, its 27.99% trailing-12-month levered FCF margin is significantly higher than the 1.44% industry average. Furthermore, its 0.51x trailing-12-month asset turnover ratio is 24.3% higher than the 0.41x industry average.
VRTX's net revenues for the fiscal second quarter that ended on June 30, 2024, increased 6.1% year-over-year to $2.64 billion. Its interest income grew 8.2% from the prior year's quarter to $156.50 million. Furthermore, as of June 30, 2024, the company's total liabilities and shareholders' equity stood at $20.13 billion, compared to $22.73 billion as of December 31, 2023.
Street expects VRTX's net product revenues for the quarter ended September 30, 2024, to increase 8.4% year-over-year to $2.69 billion. Its EPS for the same quarter is expected to grow 1.3% year-over-year to $4.13. It surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, VRTX's stock has gained 31.2% to close the last trading session at $474.91.
VRTX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect strong prospects. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It is ranked #72 out of 328 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. It has a B grade for Stability. <a href="https://stocknews.com/stock/VRTX/">Click here</a> to see VRTX's Growth, Value, Momentum, Sentiment, and Quality ratings.
Wave Life Sciences Ltd. (<a href="https://stocknews.com/stock/WVE/">WVE</a>) 
Based in Singapore, WVE is a clinical-stage genetic medicine company that designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug development platform. It is developing oligonucleotides that target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, and restore the production of functional proteins.
On October 16, 2024, WVE announced the first-ever therapeutic RNA editing in humans in its RestorAATion-2 trial for alpha-1 antitrypsin deficiency (AATD). The single dose of WVE-006 restored wild-type M-AAT protein, offering a potential treatment for AATD-related lung and liver disease.
In terms of the trailing-12-month asset turnover ratio, WVE's 0.50x is 22.6% higher than the 0.41x industry average.
WVE's revenue for the second quarter that ended on June 30, 2024, was $19.69 million. For the same quarter, the company's net total other income stood at $2.07 million. Moreover, as of June 30, 2024, the company's total liabilities were $204.42 million, compared to $227.45 million as of December 31, 2023.
WVE surpassed the consensus revenue estimates in three of the trailing four quarters. Over the past nine months, the stock has gained 210% to close the last trading session at $14.54.
WVE's POWR Ratings reflect a robust outlook. It has a B grade for Sentiment. It is ranked #81 out of 161 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> industry. To see WVE's additional grades for Growth, Value, Momentum, Stability, and Quality, <a href="https://stocknews.com/stock/WVE/">click here</a>.
Poseida Therapeutics, Inc. (<a href="https://stocknews.com/stock/PSTX/">PSTX</a>)
PSTX, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for hematologic malignancies include P-BCMA-ALLO1, P-CD19CD20-ALLO1, P-BCMACD19-ALLO1, and P-CD70-ALLO1.
On October 17, 2024, PSTX announced the nomination of a new allogeneic, dual CAR-T therapy development candidate under its collaboration with Roche, triggering a $15 million milestone payment. This extends PSTX's cash runway into early 2026, with a focus on treating hematologic malignancies, including multiple myeloma.
For the fiscal second quarter (ended June 30, 2024), PSTX's total revenues increased 29.8% year-over-year to $25.97 million. The company's net other income was $2.64 million, up 4% from the previous year's quarter. In addition, the company's total assets came in at $298.69 million, compared to $273.89 million as of December 31, 2023.
Analysts expect PSTX's revenue for the quarter ended September 30, 2024, to increase 73.8% year-over-year to $16.25 million. It surpassed the EPS estimates in three of the trailing four quarters. Over the past six months, PSTX's stock has gained 14.6% to close the last trading session at $2.47.
It's no surprise that PSTX has an overall rating of B, which translates to a Buy in our proprietary POWR Ratings system.
It has a B grade for Value, Sentiment, and Quality. It is ranked #34 in the Medical - Pharmaceuticals industry. Beyond what we stated above, we also have given PSTX grades for Growth, Momentum, and Stability. Get all the PSTX's ratings <a href="https://stocknews.com/stock/PSTX/">here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
VRTX shares were trading at $470.05 per share on Wednesday afternoon, down $4.86 (-1.02%). Year-to-date, VRTX has gained 15.52%, versus a 22.75% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/vrtx-wve-pstx-3-pharma-stocks-to-watch-as-gene-therapy-gains-momentum/>3 Pharma Stocks to Watch as Gene Therapy Gains Momentum</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Pharma Stocks to Watch as Gene Therapy Gains Momentum

Reports Q3 revenue $71.7M, consensus $16.27M. The company expects that its cash, cash equivalents and short-term investments of $230.9M together wi...

Poseida Therapeutics reports Q3 EPS 21c, consensus 41c

Poseida Therapeutics GAAP EPS of $0.21, revenue of $71.7M

Poseida Therapeutics, Inc. ( ($PSTX) ) has released its Q3 earnings. Here is a breakdown of the information Poseida Therapeutics, Inc. presented to...

Poseida Therapeutics Reports Strong Q3 2024 Progress

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Moderna (MRNA – Research Report), Poseida Therapeutics (PSTX – Re...

Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Poseida Therapeutics (PSTX) and Evolus (EOLS)

Virtual Investor & Analyst Cell Therapy R&D Day to be held on November 14 at 10 am. Webcast Link Published first on TheFly – the ultimate source fo...

Poseida Therapeutics holds virtual R&D Day

The latest announcement is out from Poseida Therapeutics ( ($PSTX) ). Poseida Therapeutics is making strides in cell therapy, showcasing its innova...

Poseida Therapeutics Advances in Cell Therapy Innovations

William Blair analyst Sami Corwin has maintained their bullish stance on PSTX stock, giving a Buy rating on November 8. Sami Corwin has given his B...

Poseida Therapeutics: Promising Advancements and Strategic Collaborations Drive Buy Rating

H.C. Wainwright analyst Arthur He CFA has maintained their bullish stance on PSTX stock, giving a Buy rating today. Arthur He CFA has given his Buy...

Promising Advancements in Poseida Therapeutics' Cell Therapy Drive Buy Rating

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Poseida Therapeutics (PSTX – Research Report), with a pri...

Poseida Therapeutics (PSTX) Receives a Buy from Piper Sandler

EOLS

MRNA

VRTX

Press Releases

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients

Comments

Poseida Therapeutics

Poseida Therapeutics (PSTX) Opzioni

Poseida Therapeutics (NASDAQ:PSTX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO